Eight first cheques. Top decile globally.

Digital health platform helping cancer patients manage their treatment journey — a personalised companion tracking symptoms, connecting patients to care teams, and supporting treatment adherence. Partnerships with the largest life insurers in the US and Canada; US HQ in New York. ARR AUD $5.75M. TIME Top 10 Global Health Tech 2025.

AI-powered real-time payment and loyalty platform for Gen Z consumers. Expanded across APAC — Singapore, Japan, US — building a category-defining position in next-generation consumer payments. Quarterly revenue US$16M. Recognition: AFR Fast Starters Top 10 (×2 consecutive years); Forbes Asia 100 to Watch.

AI-powered financial viability platform for the construction and infrastructure sectors. Helps project owners, contractors and financiers assess and monitor financial risk across large-scale projects — replacing manual due diligence with automated, continuous assessment. Clients include top builders across Australia and North America. ARR AUD $5M.

Monash spinout. Rare-earth-free nanocrystalline magnets run motors at near-perfect efficiency — in an electric airplane or EV, that weight saving converts directly into longer flight time. Seed+ round oversubscribed and led by SQM. Boson facilitated intros to eVTOL manufacturers EHang and Zero Gravity. Falling Walls Global Science Summit Finalist; AU 50 Most Innovative Manufacturers — Top 10 Gold.

All-in-one corporate social responsibility platform for APAC enterprises, integrating donations, gift matching and volunteer management. Notable clients include ASX, KPMG, Xero, Hong Kong Stock Exchange and GPT Group. ARR AUD $1.33M.

AINC's Manufact — an AI platform that gives engineers and manufacturers instant cost estimates and optimal manufacturing methods from a part design, cutting quote turnaround from days or weeks to seconds. Launched 2025; secured pilots with major global manufacturers. Latest round at USD $10M pre-money, led by a Silicon Valley manufacturing-specialist VC.

Digital health platform for people with disabilities. Wound down 2024. Reported at 0× per IPEV standards.

Modern publishing platform for independent media. Wound down 2024 after pivot did not reach product-market fit. Reported at 0× per IPEV standards.

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products for oncology, based on its proprietary SAR Technology platform. Its Targeted Copper Theranostic (TCT) platform utilises the pairing of copper-64 for imaging and copper-67 for therapy, delivering accuracy and precision in the treatment of a range of cancers. The clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and SARTATE, targeting prostate cancer, breast cancer, neuroendocrine tumours, and neuroblastoma.

Junshi Biosciences is an innovation-driven biopharmaceutical company founded in December 2012 by alumni of leading Chinese and US universities. Headquartered in Shanghai and operating across China and the United States, the company is dedicated to discovering, developing, and commercialising innovative therapeutics. It has built a diversified pipeline of over 50 drug candidates across five therapeutic focus areas: oncology, autoimmune, metabolic, neurological, and infectious diseases. Five products have reached markets in China or internationally, anchored by toripalimab (TUOYI®/LOQTORZI™), China's first domestically developed and approved anti-PD-1 monoclonal antibody.